<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577977</url>
  </required_header>
  <id_info>
    <org_study_id>2008/01743</org_study_id>
    <nct_id>NCT03577977</nct_id>
  </id_info>
  <brief_title>Betaferon Use in Children and Adolescents With Multiple Sclerosis</brief_title>
  <official_title>Retrospective Data Collection on Betaferon Use in Children and Adolescents With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine efficacy, safety and tolerability of interferon
      beta-1b for multiple sclerosis (MS) in children and adolescents
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2008</start_date>
  <completion_date type="Actual">April 15, 2009</completion_date>
  <primary_completion_date type="Actual">April 15, 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean expanded disability status scale (EDSS) score at the end of trial participation</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The Expanded Disability Status Scale (EDSS) score is ranged between 1 (No disability, minimal signs in one Functional System) and 10 (death due to MS) measured in half-points on an ordinal scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients having the mean EDSS score of less than or equal to 3.0 and more than or equal to 3.5 at the end of the trial</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The Expanded Disability Status Scale (EDSS) score is ranged between 1 (No disability, minimal signs in one Functional System) and 10 (death due to MS) measured in half-points on an ordinal scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean frequency of complications recorded after start of betaferon therapy</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean EDSS score on the exacerbations recorded after start of betaferon therapy</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The Expanded Disability Status Scale (EDSS) score is ranged between 1 (No disability, minimal signs in one Functional System) and 10 (death due to MS) measured in half-points on an ordinal scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events described during the trial and described as possibly, likely, or undoubtedly associated with the test drug</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of mild, moderate, or severe adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of serious adverse events described during the trial</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events described during the trial and classified as an flu-like syndrome</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events described during the trial and classified as a local reaction</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of cases of betaferon discontinuation due to adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patients treated with Betaferon</arm_group_label>
    <description>Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)</intervention_name>
    <description>Betaferon was injected subcutaneously as prescribed by the treating physician.</description>
    <arm_group_label>Patients treated with Betaferon</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple sclerosis patients under 18 years old treated with at least one dose of Betaferon
        until 31.12.2007.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with symptoms consistent with the diagnosis of a demyelinating CNS disease

          -  patients who received at least one injection of Betaferon before age 18 (before their
             18th birthday)

          -  recorded use of at least one dose of Betaferon before January 1, 2008

        Exclusion Criteria:

          -  Diagnosis other then MS or a demyelinating CNS disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis (MS), Betaseron, Betaferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

